People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Castle Creek Pharmaceuticals, LLC | — | Pharmaceuticals | Series C | $48.0M | $1.7B | 2016 |
| A&A Acquisitions, LLC | — | Other | Series B | $20.7M | $131.1M | 2024 |
Greg Licholai at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Greg Licholai on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Antonio Gracias | 1 | 15 |
| Jeffrey Aronin | 1 | 6 |
| Patrick Morris | 1 | 6 |
| Timothy Cunniff | 1 | 5 |
| Michael Derby | 1 | 5 |
| Nicholas Lovejoy | 1 | 1 |
| Kyle Coots | 1 | 1 |
| Randy Evans | 1 | 1 |
| Collin Abert | 1 | 1 |
| Aron Berke | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.